- Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective.
- GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, South Africa, China, and Canada.
- Three trials of its vaccine are in the offing - U.S. (for Malaysia), China, and Canada - all at the expense of the contracting party.
- As contracts are announced, fees are collected, and the vaccine subsidiary NGIO, is listed, the stock price will move upwards.
For further details see:
Generex Sees Way Forward With Long-Lasting Covid-19 Vaccine